GRI Bio Inc. (GRI) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

GRI Bio Inc. (GRI)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.74

0.01 (1.37%)

At close: Jan 14, 2025, 3:59 PM

0.70

-5.17%

After-hours Jan 14, 2025, 04:12 PM EST

undefined% (undefined)

Bid	0.71
Market Cap	6.61M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	77.53
PE Ratio (ttm)	0.01
Forward PE	n/a
Analyst	Buy

Ask	0.75
Volume	178,577
Avg. Volume (20D)	4,163,708
Open	0.74
Previous Close	0.73
Day's Range	0.72 - 0.76
52-Week Range	0.30 - 65.00
Beta	undefined

About GRI

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sc...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 10, 2021

Employees 4

Stock Exchange NASDAQ

Ticker Symbol GRI

Website https://www.gribio.com

Analyst Forecast

According to 2 analyst ratings, the average rating for GRI stock is "Buy." The 12-month stock price forecast is $11.5, which is an increase of 1453.21% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

2 months ago · Source

-19.57%

GRI Bio shares are trading lower after the company... Unlock content with Pro Subscription

3 months ago · Source

+25.43%

GRI Bio shares are trading higher after the company announced it presented preclinical data highlighting GRI-0621's ability to inhibit invariant natural killer T cell activity.

News

3 months ago · proactiveinvestors.co.uk

UK residential rent rises are slowing but Grainger says demand remains strong

Grainger Plc (LSE:GRI) reported slower rental growth for recent months and said it expects further slowing in the coming year. The FTSE 250-listed private landlord, which owns around 12,000 homes, sa...